Site Loading

Yiling Pharmaceutical’s first quarter profit is expected to exceed 4.3 billion Lianhua Qingwen Thailand approved

Yiling Pharmaceutical’s first quarter profit is expected to exceed 4.3 billion Lianhua Qingwen Thailand approved
Sauna Night News (reporter Li Yunqi) On March 30, the listed company Yiling Pharmaceutical released the first quarter of 2020 pre-announcement, showing a profit of 43255 in the first quarter.160 thousand yuan to 46138.840,000 yuan, compared with 28836 in the first quarter of 2019.770,000 yuan increased by 50% to 60%.Weighed by Ling Pharmaceutical, the change in performance was due to the increase in operating income of Lianhua Qingwen products in the first quarter of 2020 compared with the same period last year.In addition, Yiling Pharmaceutical announced on the same day that it received the approval for the registration of modern botanical drugs issued by the Ministry of Health of Thailand, and approved the company’s drug Lianhua Qingwen capsules to meet the registration of Thailand’s modern botanical drugs standards.”This time Lianhua Qingwen Capsule obtained the approval of the Ministry of Health of Thailand for the registration of modern botanical drugs, which marks the company’s continued qualification to sell the product as a drug in the Thai market, which has a positive impact on the company’s expansion into overseas markets.”Weighed by Ling Pharmaceutical, until now, except for Thailand, Lianhua Qingwen Capsules have been used in Hong Kong, Macao, China, Brazil, Indonesia, Canada, Mozambique., “Phytopharmaceuticals”, “Natural Health Products”, “Food Supplements” and other identities were registered for marketing approval.According to the experts of Ling Pharmaceutical, the current increase in the proportion of overseas (overseas) sales revenue in the company’s total operating income has not yet achieved scale sales, which does not have a significant impact on the company’s operating performance.In addition, pharmaceutical sales are also susceptible to changes in overseas (overseas) market policy environment, exchange rate changes, market competition and other factors.Sauna, Ye Wang Li Yunqi editor Wang Jinyu proofreading Li Shihui

Close